ANI Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts ANIP Hot Sheet
Join SI Premium – FREE
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team will present at two upcoming investor conferences as follows:
EVENT: H.C. Wainwright 27th Annual Global Investment Conference
DATE: Monday, September 8, 2025
TIME: 9:00am ET
EVENT: Morgan Stanley 23rd Annual Global Healthcare Conference
DATE: Tuesday, September 9, 2025
TIME: 1:50pm ET
The live and archived webcasts will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
Source: ANI Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
- Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure
- Ethereum and Arbitrum Price Prediction: ARB Rebounds as Remittix Offers a Completely Different Growth Story
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Morgan Stanley, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share